Clinical Trials Logo

Meningioma clinical trials

View clinical trials related to Meningioma.

Filter by:

NCT ID: NCT05821790 Not yet recruiting - Meningioma Clinical Trials

Role of the Tumor Microenvironment in Aggressive Meningiomas

MEME
Start date: May 2023
Phase:
Study type: Observational

Meningiomas are the most common primary tumors of the central nervous system in adults. High-grade forms have a high frequency of neurofibromatosis 2 (NF2) mutations and represent 25% of meningiomas, with multiple recurrences associated with morbidity and reduced survival without medical options, including immunotherapy. The meninges play a key role in neuro-immune communication through the diversity of their immune cells and the presence of meningeal lymphatic vessels (MLV). Recent data, including from our team, shows frequent infiltration of lymphocytes and myeloid cells specific to benign meningiomas. Our hypothesis is that the immune microenvironment composed of meningeal immune cells and MLVs regulates the malignant histological progression of NF2-mutated meningiomas and their immune surveillance evasion behavior This study aims to characterize the different cellular populations of the meningioma microenvironment. We will describe the exact participation of immune and vascular cell populations in the initiation and progression of meningioma, using MRI imaging and surgical biopsies of the dura mater and meningioma in patients undergoing neurosurgery for meningioma resection.

NCT ID: NCT05793034 Recruiting - Meningioma Clinical Trials

Predictive Factors for Survival in Aggressive Meningiomas

23Men
Start date: January 7, 2021
Phase: N/A
Study type: Interventional

The investigators plan to collect clinical and molecular data, including ICH, PCR, NGS and methylome, from patients operated on for grade 2 or grade 3 meningioma. The purpose of the study is to identify reliable and easy-to-assess predictive factors for recurrence and survival after surgery.

NCT ID: NCT05727605 Recruiting - Glioma Clinical Trials

Neurocognition After Radiotherapy in CNS- and Skull-base Tumors

NARCiS
Start date: February 8, 2023
Phase: N/A
Study type: Interventional

The goal of this multicenter prospective longitudinal study is to study the long-term impact of multimodal treatment (chemotherapy, radiotherapy and surgery) in adult brain and base of skull tumors on neurocognitive functioning. All included patients will complete a self-report inventory (subjective cognitive functioning, QoL, confounders), a cognitive test battery, an advanced MR at multiple timepoints. Moreover, toxicity will be scored according to the CTCAEv5.0 in these patients over time.

NCT ID: NCT05639491 Completed - Clinical trials for Petrous Apex Meningioma

Petro-trigeminal Line and Petrous Apex Cephaloceles

APEX
Start date: September 18, 2020
Phase:
Study type: Observational

cephaloceles are rare lesions of the petrous apex, inconsistently listed as meningoceles or arachnoid cysts. They're consistent with a herniation posterolateral of the Meckel cavum within the petrous apex. These lesions may be the cause of a symptomatology varied, or be discovered by chance in subjects who have not been asymptomatic. Currently, there is no evidence in the literature a simple, fast and reproducible radiological marker that allows for the diagnosis of cephaloceles of the petrous apex, in particular the small ones. The purpose of this study is to validate a radiological benchmark simple and reproducible, the trigeminal petrol line, in order to improve the diagnosis of petrous apex cephaloceles

NCT ID: NCT05630664 Recruiting - High Grade Glioma Clinical Trials

Liquid Biopsy in High-grade Gliomas and Meningiomas

SOPRANO
Start date: October 1, 2022
Phase:
Study type: Observational

The general objective of this project is to evaluate the value of cell-free DNA circulating in plasma as a marker of tumor evolution in patients with high-grade gliomas and meningiomas. To this end, we propose to longitudinally collect four samples of plasma at the following time points: - T0: before surgery; - T1: one month after surgery; - T2: one month after the end of radiotherapy; - T3 at the time of radiological progression. The goal is to evaluate whether changes in plasma concentration of circulating cell-free DNA can help predict progression-free survival, overall survival, and response to therapies.

NCT ID: NCT05576103 Recruiting - Glioma Clinical Trials

Longitudinal Prospective Study of Neurocognition & Neuroimaging in Primary BT Patients

Start date: January 2015
Phase:
Study type: Observational

In this proposal, the investigators introduce a novel, translational study to prospectively examine primary brain tumor patients undergoing fractionated radiation therapy to the brain. Quantitative neuroimaging, radiation dose information, and directed neurocognitive testing will be acquired through this study to improve understanding of cognitive changes associated with radiation dosage to non-targeted tissue, and will provide the basis for evidence-based cognitive- sparing brain radiotherapy.

NCT ID: NCT05537675 Completed - Clinical trials for Refractory Meningioma

Semi-automated Segmentation Methods of SSTR PET for Dosimetry Prediction

177Lumen
Start date: October 1, 2022
Phase:
Study type: Observational

Tumor dosimetry with somatostatin receptor-targeted peptide receptor radionuclide therapy (SSTR-targeted PRRT) by 177Lutetium-DOTATATE might contribute to improve follow-up and treatment response of refractory meningiomas. This study aims to evaluate Standard Uptake Value mean (SUVmean) as a tumoral absorbed dose predictive predictive factor and propose semi-automated segmentation method to determine metabolic tumor volume with pretherapeutic 68-Gallium-DOTATOC PET.

NCT ID: NCT05425004 Recruiting - Meningioma Clinical Trials

Cabozantinib for Patients With Recurrent or Progressive Meningioma

Start date: May 27, 2022
Phase: Phase 2
Study type: Interventional

A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma

NCT ID: NCT05416567 Recruiting - Meningioma Clinical Trials

Embolization for Meningioma

e-men
Start date: October 10, 2022
Phase: N/A
Study type: Interventional

The natural course for meningioma suggests that a majority will grow over time. Treatment is usually indicated in growing or symptomatic meningiomas. Surgery is usually primary treatment, but there is a significant risk of adverse effects. Stereotactic radiotherapy is most often reserved to treat relapses after surgery, and except for surgery and radiotherapy there are no other established treatment methods. Endovascular embolization may be used in selected cases as a preoperative adjunct to reduce intraoperative bleeding. There is a need for more treatment options in patients with meningioma, both in uncomplicated, asymptomatic cases and in more complex cases. The aim of this study is to assess radiological and clinical results of therapeutic endovascular embolization for meningioma

NCT ID: NCT05305378 Not yet recruiting - Clinical trials for Aneurysm, AVM, Dural Arteriovenous Fistula, Glioma, Meningioma, Metastasis, Bypass

Intraoperative Laser Speckle Contrast Imaging of Cerebral Blood Flow

Start date: April 15, 2022
Phase: N/A
Study type: Interventional

The purpose of the proposed study is to investigate the usefulness of laser speckle contrast imaging (LSCI) compared to indocyanine green angiography (ICGA). We will collect data from a wide variety of neurovascular surgical procedures to determine when the technology is the most clinically useful. The intraoperative LSCI system provides high resolution images of blood flow in real-time without tissue contact and without the need for an exogenous contrast agent. Further study is needed to gain a better understanding of the use of the technique during surgery, but initial results suggest that the ability to identify blood flow changes with immediate feedback to the surgeon could be a significant advantage during many procedures.